Treats hypertension. ANDA 202170, held by Torrent Pharmaceuticals. Felodipine.
As of Nov 18, 2026, ANDA 202170 (Felodipine), held by Torrent Pharmaceuticals, was first approved by FDA on Nov 28, 2011, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Felodipine extended-release tablets are indicated for the treatment of hypertension. Felodipine extended-release tablets may be used alone or concomitantly with other antihypertensive agents.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 28, 2011 | Original application | Approved | None posted |
| Felodipine2.5MG · tablet, extended release;oral | Felodipine | Rx |
| Felodipine5MG · tablet, extended release;oral | Felodipine | Rx |
| Felodipine10MG · tablet, extended release;oral | Felodipine | Rx |
| May 23, 2012 | Supplement 1Manufacturing | Approved | None posted |
| Nov 28, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters